Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients (Q33243661)

24 July 2017

0 references

1 reference

title

Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients (English)

1 reference

24 July 2017

0 references

0 references

1 reference

Sven Trelle

7

0 references

Julia Bohlius

object named as

Julia Bohlius

1

0 references

Sue Bayliss

object named as

Sue Bayliss

9

0 references

Benjamin Djulbegovic

10

object named as

Benjamin Djulbegovic

1 reference

24 July 2017

2

Jayne Wilson

1 reference

24 July 2017

3

Jerome Seidenfeld

1 reference

24 July 2017

5

Guido Schwarzer

1 reference

24 July 2017

6

Josie Sandercock

1 reference

24 July 2017

8

Olaf Weingart

1 reference

24 July 2017

12

Simon Langensiepen

1 reference

24 July 2017

13

Chris Hyde

1 reference

24 July 2017

14

Andreas Engert

1 reference

24 July 2017

Margaret Piper

4

1 reference

PubMed ID

16705125

24 July 2017

Charles L Bennett

11

1 reference

PubMed ID

16705125

24 July 2017

language of work or name

English

0 references

publication date

1 May 2006

1 reference

Journal of the National Cancer Institute

24 July 2017

1 reference

24 July 2017

98

1 reference

24 July 2017

10

1 reference

24 July 2017

708-714

1 reference

Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials

24 July 2017

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ189

Erythropoietin, uncertainty principle and cancer related anaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ189

Erythropoietin for patients with malignant disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ189

Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ189

Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ189

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ189

Erythropoietin treatment under polychemotherapy in patients with gynecologic malignancies: a prospective, randomized, double-blind placebo-controlled multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ189

Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ189

Double-blind randomized control trial of the effect of recombinant human erythropoietin on chemotherapy-induced anemia in patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ189

Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ189

Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ189

A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ189

Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ189

Prevention of anemia in patients with solid tumors receiving platinum-based chemotherapy by recombinant human Erythropoietin (rHuEpo): a prospective, open label, randomized trial by the Hellenic Cooperative Oncology Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ189

Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ189

Effect of recombinant human erythropoietin on quality of life in cancer patients receiving chemotherapy: results of a randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ189

Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ189

Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ189

The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ189

Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ189

Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ189

Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ189

Erythropoietin regulates tumour growth of human malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ189

Beneficial and ominous aspects of the pleiotropic action of erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ189

Impact of epoetin beta on quality of life in patients with malignant disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ189

21 January 2018

Identifiers

DOI

10.1093/JNCI/DJJ189

1 reference

24 July 2017

1 reference

PubMed ID

16705125